ACA vs VATE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

ACA

52.2
AI Score
VS
ACA Wins

VATE

39.3
AI Score

Investment Advisor Scores

ACA

52score
Recommendation
HOLD

VATE

39score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric ACA VATE Winner
Forward P/E 29.8507 4.8591 VATE
PEG Ratio 1.8642 0 Tie
Revenue Growth 1.7% 74.2% VATE
Earnings Growth 448.6% 0.0% ACA
Tradestie Score 52.2/100 39.3/100 ACA
Profit Margin 16.8% -1.5% ACA
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY ACA

Relative Price Performance (Last 90 Days)

ACA 1M: +0.9% · 3M: +0.9% VATE 1M: +0.8% · 3M: -49.8%

Current Technical Phase

ACA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 65

RSI (14): 65.1 · Price: $146.71

VATE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -20.1%), weak momentum, RSI 45

RSI (14): 45.0 · Price: $7.44

Fundamentals Snapshot

Metric ACA VATE
Market Cap — —
Forward P/E 28.6 4.9
Trailing P/E 32.6 —
Revenue (TTM) — —
Revenue Growth 0.0% 0.7%
Gross Margin 0.2% 0.2%
Operating Margin 0.1% 0.1%
EPS 4.48 -1.79
Dividend Yield 0.00% 0.00%

Frequently Asked Questions

Based on our detailed analysis, ACA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.